Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients

Journal of Hypertension

Volumn 18, Issue 3, 2000, Pages 327-337

  Chalmers, John ^a   Castaigne, Alain ^b   Morgan, Trefor ^c   Chastang, Claude ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Combination therapy; Elderly; Hypertension; Indapamide; Low dose; Perindopril

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL;

AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; ENDOCRINE DISEASE; ESSENTIAL HYPERTENSION; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEARING DISORDER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; SUPINE POSITION; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TABLET; VASCULAR DISEASE; VERTIGO; VESTIBULAR DISORDER; VOMITING;

EID: 0034010827     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018030-00013     Document Type: Article

References (41)

1. References 1 Lew EA. Hypertension and longevity. In: Laragh JH, Brenner BM, (editors): Hypertension: pathophysiology, diagnosis and management. New York: Raven Press; 1990. pp. 175-190.
2. 2 Kannel WB, Dannenberg AL, Abbott RD. Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J 1985; 109:581-585.
3. 3 Pepine CJ, Abrams J, Marks RG, Morris JJ, Scheidt SS, Handberg E, for the TIDES Investigators. Characteristics of a contemporary population with angina pectoris. Am J Cardiol 1994; 74:226-231.
4. 4 Chamontin B, Poggi L, Lang T, Ménard J, Chevalier H, Gallois H, et al. Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998; 11:759-762.
5. 5 Keil U, Remmers A, Chambless L, Hense HW, Stieber J, Lauck A. Epidemiologie des Bluthochdruckes-Häufigkeit, Verteilung, Bekanntheits und Behandlungsgrad der Hypertonie in der Hansetstadt Lübeck. Ergebnisse der Lübecker Blutdruckstudie und Vergleich mit Daten der Münchener Blutdruckstudie. Münch Med Wochenschr 1986; 128:424-429.
6. 6 Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305-313.
7. 7 Smith WM. Hypertension in the elderly, West J Med 1990; 152:414-416.
8. 8 Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16:747-752.
9. 9 MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients; an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15:967-978.
10. 10 Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L. Aguilar C. Hypertension in the elderley. Implications and generalizability of randomised trials. JAMA 1994; 272:1932-1938.
11. 11 Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, et al. Drug treatment of hypertension in the elderly: A meta-analysis. Ann Intern Med 1994; 121:355-362.
12. 12 Mancia G, Failla M, Grappiolo A, Giannattasio C. Present and future role of combination treatment in hypertension. J Cardiovasc Pharmacol 1998; 31 (suppl 2):S41-S44.
13. 13 Psaty BM, Koepsell TD, Yanez ND, Smith NL, Manolio TA, Heckbert SR, et al Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. An effect of the major clinical trials on clinical practice? JAMA 1995; 273:1436-1438.
14. 14 Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
15. 15 Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control. J Hypertens 1996; 14:929-933.
16. 16 O'Malley K, Cox JP, O'Brien E. Choice of drug treatment for elderly hypertensive patients. Am J Med 1991; 90 (suppl 3A):27S-33S.
17. 17 Freis ED, Papademetriou V. Current drug treatment and treatment patterns with antihypertensive drugs. Drugs 1996; 52:1-16.
18. 18 Aellig WH. Adverse reactions to antihypertensive therapy. Cardiovasc Drugs Ther 1998; 12:189-196.
19. 19 Safar M, Zanchetti A, Sever PS, Anlauf M, Calvo Gomez C, De Leeuw PW, et al. Perindopril and indapamide as a combination in the treatment of mild to moderate hypertension: a double-blind, randomized placebo controlled european multicenter study. Am J Hypertens 1994; 7:42A-43A.
20. 20 Castaigne A, Chalmers J, Morgan T, Chastang C, Feldmann L, Guez D. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension. Clin Exp Hypertens 1999; 21:1097-1110.
21. 21 Gennari FJ, Hypokalaemia. N Engl J Med 1998; 7:451-458.
22. 22 Amery A, Birkenhäger WH, Bulpitt CJ, Dollery CT. The European working party on high blood pressure in the elderly. Am J Med 1991; 90:1S-70S.
23. 23 Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
24. 24 MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-412.
25. 25 Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
26. 26 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
27. 27 Holzgreve H. Therapeutic needs of the elderly patient. J Cardiovasc Pharmacol 1998; 31 (suppl 2):S22-S26.
28. 28 Du X, Cruickshank K, McNamee R, Saraee M, Sourbutts J, Summers A, et al. Case-control study of stroke and the quality of hypertension control in north west England. BMJ 1997; 314:272-276.
29. 29 Fletcher AE, Palmer AJ, Bulpitt CJ. Cough with angiotensin-converting enzyme inhibitors: how much of a problem? J Hypertens 1994; 12 (suppl 2):S43-S47.
30. 30 Yeo WW, Ramsay LE. Persistent dry cough with enalapril: incidence depends on methods used. J Hum Hypertens 1990; 4:517-520.
31. 31 Holwerda NJ, Fogari R, Angell P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14:1147-1151.
32. 32 Neutel JM, Smith DHG, Reilly PA. The efficacy and safety of Telmisartan compared to Enlapril in patients with severe hypertension. Int J Clin Pract 1999; 53:175-178.
33. 33 Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: a critical review. J Clin Hypertens 1987; 3:278-293.
34. 34 Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med 1994; 154:1430-1431.
35. 35 Neutel JM, Rolf CN, Valentine SN, Li J, Lucas C, Marmorstein BL. Low-dose combination therapy as first line treatment of mild-to-moderate hypertension: the efficacy and safety of bisoprolol/hctz versus amlodipine, enalapril and placebo. CVR&R 1996; 11:111-120.
36. 36 Waeber B, Brunner HR. Main objectives and new aspects of combination treatment of hypertension. J Hypertens 1995; 13:S15-S19.
37. 37 Luscher TF, Vetter H, Siegenthaler W, Vetter W. Compliance in hypertension: facts and concepts. J Hypertens 1985; 3 (suppl 1):3-9.
38. 38 Sica DA. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs 1994; 48:16-24.
39. 39 Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150:1881-1884.
40. 40 Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9 (suppl 2):S15-S18.
41. 41 Chalmers J. 1999 World Health Organization - international society of hypertension guidelines for the management of hypertension. Guidelines subcommittee. J Hypertens 1999; 17:151-183.